Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors

American Journal of Dermatopathology

Volumn 20, Issue 1, 1998, Pages 12-16

  Sparrow, Louis E ^a,b   English, D R ^a   Taran, J M ^a   Heenan, P J ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Immunohistochemistry; Melanocytic Tumors; MIB 1; Prognosis; Proliferative activity; Thin melanomas

Indexed keywords

CELL MARKER; MIB 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTE; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; AUTOANTIGENS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 0031891403     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-199802000-00003     Document Type: Article

References (19)

1. Heenan PJ, English DR, Holman CDJ, et al. Survival among patients with clinical stage cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981. Cancer 1991; 68:2079-87.
2. Gromet MA, Epstein WL, Blois MS. The regressing thin melanoma. Cancer 1978;42:2282-93.
3. Balch CM, Soong SJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton A., Sober AJ, Milton GW, Soong SJ, eds. Cutaneous melanoma. 2nd ed. Philadelphia: J.B. Lippincott; 1992:165-87.
4. Jochum W, Schroder S, Al-Taha R, et al. Prognostic significance of nuclear DNA content and proliferate activity in renal cell carcinomas. Cancer 1996;77:514-21.
5. Wakimoto H, Aoyagi M, Nakyama T, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996; 77:373-80.
6. Gerdes J, Schwab V, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;32:13-20.
7. Key G, Becker MHG, Baron B, et al. New Ki-67 equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62-base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68:629-36.
8. Kahn HJ. MIB-1 proliferative activity in primary and metastatic melanomas. Br J Dermatol 1993 129(suppl 42):18. Abstract.
9. Gelschleichter L, Gown AM, Zarbo RJ. p53 and mdm-2 Expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995;8:530-5.
10. Soyer HP. Ki67 Immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Culan Pathol 1991;18:264- 72.
11. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. Am J Dermatopathol 1989;11:301-7.
12. Saenz-Santamaria M, Reed JA, McNutt S, et al. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 1994;21:393-7.
13. Kanter L, Biegen J, Wejde B, et al. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevo- cellular naevus-like lesions with malignant properties. Melanoma Res 1995;5:345-50.
14. Ramsay J, From L, Iscoe NA, et al. MIB-1 Proliferative activity is a significant prognostic factor in primary thick cutaneous melanoma. J Invest Dermatol 1995;105:22-6.
15. Reddy V, Aranha G, Potocki D. el al. Cell proliferation markers in predicting outcome in malignant melanoma. J Lab Invest 1994;70:48A.
16. Evans AT, Blessing K, Orrell JM, et al. Mitotic indices, anti-PCNA immunostaining, and AgNOR's in thick cutaneous melanomas displaying paradoxical behaviour. J Pathol 1992;168:15- 22.
17. Woosley JT, Dietrick DT. Prognostic Significance of PCNA grade in malignant melanoma. J Cutan Pathol 1993;20:498-503.
18. Hendricks JB, Wilkinson EJ. Quality control considerations for Ki-67 detection and quantitation in paraffin-embedded tissue. J Cellular Biochem. 1994;19(suppl):105-10.
19. Boni R, Doguoglu D, Burg G, et al. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416-8.